Key result
Updated Indian lipid guidelines prioritize LDL-C and non-HDL-C targets and support routine non-fasting profiles.
Why the study?
The recent Indian lipid management guidelines emphasize specific lipid targets and risk modifiers, but practical implementation details for biochemistry reporting and patient compliance need clarification.
Answers are grounded in this paper and cite their sources.
The review highlights the latest Indian guidelines for dyslipidemia, emphasizing LDL-C as the primary target and the utility of non-fasting lipid profiles.
The recent lipid management guidelines emphasize using low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (non-HDL-C), and apo B levels as treatment targets.Out of these, LDL-C is the primary target of lipid management, non-HDL-C is the co-primary and ApoB is the secondary target.One-time estimation of lipoprotein(a) is sufficient presently to assess risk in view of the lack of specific drugs targeting it.Triglyceride levels ≥150 mg/dL in fasting and ≥175 mg/dL in non-fasting samples are considered risk modifiers for atherosclerotic cardiovascular disease.Lipid profile estimation in a non-fasting sample is considered good enough to manage a dyslipidemia patient.The inclusion of risk group-specific target range of lipid profile in biochemistry report format shall be more informative and helpful in ensuring better patient compliance.
No takes yet. Share an insight, caveat, or question.
Shalini Gupta (2024) conducted a review in Dyslipidemia. The latest Indian guidelines for dyslipidemia management emphasize LDL-C as the primary target, non-HDL-C as co-primary, and ApoB as secondary, while supporting non-fasting lipid profile estimation.
Synapse has enriched 10 related papers. Consider them for comparative context: